Protalix BioTherapeutics, Inc. (NYSEAM: PLX)
Health Care · Biotechnology · US
$2.78
0.00% today · +8.6% 1Y
Protalix BioTherapeutics, Inc. (NYSEAM: PLX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $223.99M and employs 226 people.
Over the last twelve months the share price has gained 8.6%, trading between 1.60 and 3.19.
Tweenvest scores Protalix BioTherapeutics, Inc. across four factors: quality 59/100, value 25/100, growth 0/100. Its strongest factor is quality.
PLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $223.99M
- Revenue (TTM)
- $80.62M
- P/E
- 11.76
- EPS
- 0.24
- Dividend yield
- —
- Beta (5Y)
- -0.09
- 52-week high
- $3.19
- 52-week low
- $1.60
- Avg volume (3M)
- —
- Shares outstanding
- 80.57M
- Employees
- 226
- Next earnings
- —
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
- ISIN
- US74365A3095
- Listed since
- May 15, 1998
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Valerio Therapeutics Société anonymeENXTPA: ALVIO | $229.28M | €0.41 | +7.61% |
| Spectral Medical Inc.TSX: EDT | $228.66M | CA$1.11 | -5.53% |
| Evommune, Inc.NYSE: EVMN | $226.83M | $6.06 | -3.04% |
| ImmuneOncia Therapeutics, Inc.KOSDAQ: A424870 | $224.36M | ₩3,300.00 | -4.21% |
| ToolGen IncorporatedKOSDAQ: A199800 | $223.81M | ₩33,450.00 | -3.18% |
| Akebia Therapeutics, Inc.NasdaqCM: AKBA | $221.99M | $0.80 | -0.32% |
| Sionna Therapeutics, Inc.NasdaqGM: SION | $221.54M | $4.71 | -3.88% |
| OBI Pharma, Inc.TPEX: 4174 | $220.98M | NT$53.70 | +27.86% |
Figures last refreshed Oct 11, 2026.